Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Single-source drug launches in GLOBE/GUARD European reference markets fall 27% in first 17 months since MFN EO, reveals GlobalData

Some 27% fewer new pharmaceutical active ingredients (i.e. new single-source brands) were launched in the European reference markets under the GLOBE and GUARD MFN Medicare demonstration models in the 17 months after President Donald Trump published his Most Favored Nation (MFN) executive order (EO), compared to the prior 17-month period, according to the latest analysis […]
Read more

Diagnosed incident cases of glioblastoma across 8MM to reach over 66,000 in 2035, forecasts GlobalData

The diagnosed incident cases of glioblastoma (GBM) in the eight major markets (8MM*) are set to increase at an annual growth rate (AGR) of 0.81% from over 61,000 in 2025 to over 66,000 in 2035, forecasts GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Glioblastoma (GBM): Epidemiology Report and Forecast[SP1]  to 2035,” reveals […]
Read more

Merck’s non-oncology diversification to cushion looming Keytruda patent cliff, reveals GlobalData

Merck & Co’s blockbuster oncology product Keytruda (pembrolizumab), which has generated over half of the company’s total revenue in the last three years, faces key patent expirations and market rivalry from 2028. Consequently, Keytruda’s projected 2032 revenues are slated to plummet by 57% relative to 2025 performance. However, the company’s non-oncology portfolio is forecasted to […]
Read more

Ulcerative colitis burden across 7MM to exceed 2.36 million cases by 2035, forecasts GlobalData

The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7MM*) are projected to reach over 2.36 million by 2035. Driven by an expanding patient base, this upward epidemiological trajectory highlights a rising burden on healthcare systems. Stable incidence growth underscores the critical need for advanced clinical approaches to manage long-term disease […]
Read more

China emerges as a global epicenter for obesity innovation, says GlobalData

China is emerging as an innovation hub in the rapidly diversifying global obesity drug landscape, with domestic drugmakers making proven incretin therapies more convenient while developing novel mechanisms beyond conventional GLP-1 therapy, according to GlobalData, a leading intelligence and productivity platform. According to GlobalData Pharma Intelligence Center, the number of diagnosed prevalent cases for obesity […]
Read more
,

US CMS will face challenges in implementation of GLOBE model for MFN pricing, says GlobalData

The US Centers for Medicare and Medicaid Services (CMS) has released the final guidelines for implementation of the GLOBE Most Favored Nation (MFN) pricing model. GlobalData, a leading intelligence and productivity platform, with many years of experience in drug pricing and international reference pricing (IRP) analysis, has produced research highlighting the difficulties CMS will face […]
Read more

Radiopharmaceutical growth is outpacing manufacturing infrastructure, says GlobalData

The rapid growth of radiopharmaceuticals is creating pressure on the manufacturing and supply infrastructure needed to support new diagnostic and cancer treatments. The global radiopharmaceutical market is estimated to be worth approximately $11 billion in 2026 and is projected to exceed $20 billion by 2030, says GlobalData, a leading intelligence and productivity platform. GlobalData’s monthly […]
Read more

Amyotrophic lateral sclerosis diagnosed prevalent cases to reach over 86,800 across 8MM in 2035, forecasts GlobalData

The burden of diagnosed prevalent cases of amyotrophic lateral sclerosis in the 8MM* is forecast to increase at an annual growth rate (AGR) of 0.71% from approximately 81,100 in 2025 to over 86,800 cases in 2035, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Amyotrophic Lateral Sclerosis (ALS): Epidemiology Forecast to […]
Read more

Tirzepatide holds potential to outperform oral and injectable semaglutide for glycemic control and weight-loss in T2D, says GlobalData

Eli Lilly’s Mounjaro (tirzepatide) was more effective than both Novo Nordisk’s injectable Ozempic and oral Rybelsus (semaglutide) in helping adults with type 2 diabetes (T2D) achieve glycemic and weight-loss targets, according to real-world evidence presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results highlight tirzepatide’s potential to address […]
Read more

Semaglutide dose escalation holds promise for cardiovascular edge over tirzepatide switch in T2D, says GlobalData

Adults with type 2 diabetes (T2D) who escalated their dose of Novo Nordisk’s Ozempic (semaglutide) experienced a lower observed risk of cardiovascular events than those who switched to Eli Lilly’s Mounjaro (tirzepatide), according to real-world cardiovascular outcomes data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results provide […]
Read more

Oral semaglutide holds potential as alternative to injectable GLP-1s for weight loss, says GlobalData

New real-world data from the OCTANE study shows that patients who were overweight or had obesity continued to lose weight after switching from Novo’s injectable Wegovy (semaglutide) or Lilly’s Zepbound (tirzepatide) to the oral semaglutide. The findings, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, support oral semaglutide as […]
Read more

Orforglipron holds potential as differentiated oral option for weight and glycemic control in T2D, says GlobalData

Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Lilly’s Foundayo (orforglipron) was associated with greater reductions in both body weight and HbA1c than Novo’s Rybelsus (semaglutide) in adults with type 2 diabetes (T2D) who were overweight or had obesity. The results highlight orforglipron’s potential as a […]
Read more

Genentech’s approval in breast cancer among nine key value-driving biopharma catalysts in Q4 2026, reveals GlobalData

Several keenly anticipated approval decisions governing critical catalysts that can shape biopharma sentiment are expected in Q4 2024, alongside key clinical trial milestones that could influence the industry’s landscape. One of them is Genentech’s/Roche’s giredestrant, which faces two regulatory decisions in breast cancer; one is an  approval decision by November 30, for early-stage ER+/HER2- breast […]
Read more

GlobalData Healthcare to host webinar on China’s next frontier in biopharma dealmaking

China’s biopharma sector is moving from a sourcing option to a strategic priority for global pharma, with deal structures shifting from single-asset licensing to full platform acquisitions. To help healthcare and life sciences leaders navigate this shift, GlobalData Healthcare, the pharmaceutical and life sciences intelligence arm of GlobalData, a leading intelligence and productivity platform, will […]
Read more

China expands role in manufacturing new FDA-approved drugs, says GlobalData

Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signaling growing industry confidence in using the country as one of the bases for its manufacturing, according to GlobalData, a leading intelligence and productivity platform. Katia Djebbar, Pharma Analyst at GlobalData, comments: “The FDA-approved products currently being […]
Read more

South Korea’s dry eye market to see intensified competition with third homegrown drug approval, says GlobalData

South Korea’s Ministry of Food and Drug Safety has approved recoflavone (Latica/Recodu) for moderate to severe dry eye disease. Developed jointly by GL PharmaTech and Aju Pharmaceutical, recoflavone is the first domestically developed dry eye disease treatment approved in South Korea and the third prescription treatment authorized for the indication. The approval is expected to […]
Read more
1 2 3 … 111